

CC or send an email to license@isb-sib.ch

or send an email to license@sib.ch.

Result ID	Score
SPUT-LIGAND	45.51
BEST LOCAL SIMILARITY	57.11
ATTACHES	6
CHARACTERS	2
PREDICTED	No
MISMATCHES	4
INDELS	0
CAPS	0;
OR	
1	PENSTYLAKRKG
14	
DB	52 FASPRALYRHEG
65	
RESULT 13	
SPUT-LIGAND	STANDARD:
ID	SPUT-LIGAND
PPT	748 AA.
1	SGFPLKQEGK
2	DT
3	DT
4	DT
5	DT
6	DT
7	DT
8	DT
9	DT
10	DT
11	DT
12	DT
13	DT
14	DT
15	DT
16	DT
17	DT
18	DT
19	DT
20	DT
21	DT
22	DT
23	DT
24	DT
25	DT
26	DT
27	DT
28	DT
29	DT
30	DT
31	DT
32	DT
33	DT
34	DT
35	DT
36	DT
37	DT
38	DT
39	DT
40	DT
41	DT
42	DT
43	DT
44	DT
45	DT
46	DT
47	DT
48	DT
49	DT
50	DT
51	DT
52	DT
53	DT
54	DT
55	DT
56	DT
57	DT
58	DT
59	DT
60	DT
61	DT
62	DT
63	DT
64	DT
65	DT
66	DT
67	DT
68	DT
69	DT
70	DT
71	DT
72	DT
73	DT
74	DT
75	DT
76	DT
77	DT
78	DT
79	DT
80	DT
81	DT
82	DT
83	DT
84	DT
85	DT
86	DT
87	DT
88	DT
89	DT
90	DT
91	DT
92	DT
93	DT
94	DT
95	DT
96	DT
97	DT
98	DT
99	DT
100	DT
101	DT
102	DT
103	DT
104	DT
105	DT
106	DT
107	DT
108	DT
109	DT
110	DT
111	DT
112	DT
113	DT
114	DT
115	DT
116	DT
117	DT
118	DT
119	DT
120	DT
121	DT
122	DT
123	DT
124	DT
125	DT
126	DT
127	DT
128	DT
129	DT
130	DT
131	DT
132	DT
133	DT
134	DT
135	DT
136	DT
137	DT
138	DT
139	DT
140	DT
141	DT
142	DT
143	DT
144	DT
145	DT
146	DT
147	DT
148	DT
149	DT
150	DT
151	DT
152	DT
153	DT
154	DT
155	DT
156	DT
157	DT
158	DT
159	DT
160	DT
161	DT
162	DT
163	DT
164	DT
165	DT
166	DT
167	DT
168	DT
169	DT
170	DT
171	DT
172	DT
173	DT
174	DT
175	DT
176	DT
177	DT
178	DT
179	DT
180	DT
181	DT
182	DT
183	DT
184	DT
185	DT
186	DT
187	DT
188	DT
189	DT
190	DT
191	DT
192	DT
193	DT
194	DT
195	DT
196	DT
197	DT
198	DT
199	DT
200	DT
201	DT
202	DT
203	DT
204	DT
205	DT
206	DT
207	DT
208	DT
209	DT
210	DT
211	DT
212	DT
213	DT
214	DT
215	DT
216	DT
217	DT
218	DT
219	DT
220	DT
221	DT
222	DT
223	DT
224	DT
225	DT
226	DT
227	DT
228	DT
229	DT
230	DT
231	DT
232	DT
233	DT
234	DT
235	DT
236	DT
237	DT
238	DT
239	DT
240	DT
241	DT
242	DT
243	DT
244	DT
245	DT
246	DT
247	DT
248	DT
249	DT
250	DT
251	DT
252	DT
253	DT
254	DT
255	DT
256	DT
257	DT
258	DT
259	DT
260	DT
261	DT
262	DT
263	DT
264	DT
265	DT
266	DT
267	DT
268	DT
269	DT
270	DT
271	DT
272	DT
273	DT
274	DT
275	DT
276	DT
277	DT
278	DT
279	DT
280	DT
281	DT
282	DT
283	DT
284	DT
285	DT
286	DT
287	DT
288	DT
289	DT
290	DT
291	DT
292	DT
293	DT
294	DT
295	DT
296	DT
297	DT
298	DT
299	DT
300	DT
301	DT
302	DT
303	DT
304	DT
305	DT
306	DT
307	DT
308	DT
309	DT
310	DT
311	DT
312	DT
313	DT
314	DT
315	DT
316	DT
317	DT
318</td	

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

90k protein - protein search, using sw model

Run on: October 2, 2003, 14:30:16 | Search time 94 Seconds

(without alignments)
45,924 Million cell updates/sec

Perfect score: 99

Sequence: 1 PERESTREKOVYI 16

Scoring table: BLOSUM62

Gapop: 0.5

Searched: 893525 seqs., 25052604 residues

Total number of hits satisfying chosen parameter: 830525

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximun Match 100%

Listing first 65 summaries

Database : SPBML23*

1: sp-bacteria:*

2: sp-fungi:*

3: sp-insecta:*

4: sp-mammal:*

5: sp-mollusk:*

6: sp-nemat:*

7: sp-plant:*

8: sp-plantae:*

9: sp-virus:*

10: sp-worm:*

11: sp-zoobiont:*

12: sp-zooplankton:*

13: sp-zoophyte:*

14: sp-zoosporozoite:*

15: sp-zoocyst:*

16: sp-bacteriophage:*

17: sp-archaea:*

18: sp-organelle:*

19: sp-phage:*

20: sp-plant:*

21: sp-plantae:*

22: sp-virus:*

23: sp-zoobiont:*

24: sp-zooplankton:*

25: sp-zoophyte:*

26: sp-zoosporozoite:*

27: sp-zoocyst:*

28: sp-bacteriophage:*

29: sp-organelle:*

30: sp-phage:*

31: sp-plant:*

32: sp-plantae:*

33: sp-virus:*

34: sp-zoobiont:*

35: sp-zooplankton:*

36: sp-zoophyte:*

37: sp-zoosporozoite:*

38: sp-zoocyst:*

39: sp-bacteriophage:*

40: sp-organelle:*

41: sp-phage:*

42: sp-plant:*

43: sp-plantae:*

44: sp-virus:*

45: sp-zoobiont:*

46: sp-zooplankton:*

47: sp-zoophyte:*

48: sp-zoosporozoite:*

49: sp-zoocyst:*

50: sp-bacteriophage:*

51: sp-organelle:*

52: sp-phage:*

53: sp-plant:*

54: sp-plantae:*

55: sp-virus:*

56: sp-zoobiont:*

57: sp-zooplankton:*

58: sp-zoophyte:*

59: sp-zoosporozoite:*

60: sp-zoocyst:*

61: sp-bacteriophage:*

62: sp-organelle:*

63: sp-phage:*

64: sp-plant:*

65: sp-plantae:*

66: sp-virus:*

67: sp-zoobiont:*

68: sp-zooplankton:*

69: sp-zoophyte:*

70: sp-zoosporozoite:*

71: sp-zoocyst:*

72: sp-bacteriophage:*

73: sp-organelle:*

74: sp-phage:*

75: sp-plant:*

76: sp-plantae:*

77: sp-virus:*

78: sp-zoobiont:*

79: sp-zooplankton:*

80: sp-zoophyte:*

81: sp-zoosporozoite:*

82: sp-zoocyst:*

83: sp-bacteriophage:*

84: sp-organelle:*

85: sp-phage:*

86: sp-plant:*

87: sp-plantae:*

88: sp-virus:*

89: sp-zoobiont:*

90: sp-zooplankton:*

91: sp-zoophyte:*

92: sp-zoosporozoite:*

93: sp-zoocyst:*

94: sp-bacteriophage:*

95: sp-organelle:*

96: sp-phage:*

97: sp-plant:*

98: sp-plantae:*

99: sp-virus:*

100: sp-zoobiont:*

101: sp-zooplankton:*

102: sp-zoophyte:*

103: sp-zoosporozoite:*

104: sp-zoocyst:*

105: sp-bacteriophage:*

106: sp-organelle:*

107: sp-phage:*

108: sp-plant:*

109: sp-plantae:*

110: sp-virus:*

111: sp-zoobiont:*

112: sp-zooplankton:*

113: sp-zoophyte:*

114: sp-zoosporozoite:*

115: sp-zoocyst:*

116: sp-bacteriophage:*

117: sp-organelle:*

118: sp-phage:*

119: sp-plant:*

120: sp-plantae:*

121: sp-virus:*

122: sp-zoobiont:*

123: sp-zooplankton:*

124: sp-zoophyte:*

125: sp-zoosporozoite:*

126: sp-zoocyst:*

127: sp-bacteriophage:*

128: sp-organelle:*

129: sp-phage:*

130: sp-plant:*

131: sp-plantae:*

132: sp-virus:*

133: sp-zoobiont:*

134: sp-zooplankton:*

135: sp-zoophyte:*

136: sp-zoosporozoite:*

137: sp-zoocyst:*

138: sp-bacteriophage:*

139: sp-organelle:*

140: sp-phage:*

141: sp-plant:*

142: sp-plantae:*

143: sp-virus:*

144: sp-zoobiont:*

145: sp-zooplankton:*

146: sp-zoophyte:*

147: sp-zoosporozoite:*

148: sp-zoocyst:*

149: sp-bacteriophage:*

150: sp-organelle:*

151: sp-phage:*

152: sp-plant:*

153: sp-plantae:*

154: sp-virus:*

155: sp-zoobiont:*

156: sp-zooplankton:*

157: sp-zoophyte:*

158: sp-zoosporozoite:*

159: sp-zoocyst:*

160: sp-bacteriophage:*

161: sp-organelle:*

162: sp-phage:*

163: sp-plant:*

164: sp-plantae:*

165: sp-virus:*

166: sp-zoobiont:*

167: sp-zooplankton:*

168: sp-zoophyte:*

169: sp-zoosporozoite:*

170: sp-zoocyst:*

171: sp-bacteriophage:*

172: sp-organelle:*

173: sp-phage:*

174: sp-plant:*

175: sp-plantae:*

176: sp-virus:*

177: sp-zoobiont:*

178: sp-zooplankton:*

179: sp-zoophyte:*

180: sp-zoosporozoite:*

181: sp-zoocyst:*

182: sp-bacteriophage:*

183: sp-organelle:*

184: sp-phage:*

185: sp-plant:*

186: sp-plantae:*

187: sp-virus:*

188: sp-zoobiont:*

189: sp-zooplankton:*

190: sp-zoophyte:*

191: sp-zoosporozoite:*

192: sp-zoocyst:*

193: sp-bacteriophage:*

194: sp-organelle:*

195: sp-phage:*

196: sp-plant:*

197: sp-plantae:*

198: sp-virus:*

199: sp-zoobiont:*

200: sp-zooplankton:*

201: sp-zoophyte:*

202: sp-zoosporozoite:*

203: sp-zoocyst:*

204: sp-bacteriophage:*

205: sp-organelle:*

206: sp-phage:*

207: sp-plant:*

208: sp-plantae:*

209: sp-virus:*

210: sp-zoobiont:*

211: sp-zooplankton:*

212: sp-zoophyte:*

213: sp-zoosporozoite:*

214: sp-zoocyst:*

215: sp-bacteriophage:*

216: sp-organelle:*

217: sp-phage:*

218: sp-plant:*

219: sp-plantae:*

220: sp-virus:*

221: sp-zoobiont:*

222: sp-zooplankton:*

223: sp-zoophyte:*

224: sp-zoosporozoite:*

225: sp-zoocyst:*

226: sp-bacteriophage:*

227: sp-organelle:*

228: sp-phage:*

229: sp-plant:*

230: sp-plantae:*

231: sp-virus:*

232: sp-zoobiont:*

233: sp-zooplankton:*

234: sp-zoophyte:*

235: sp-zoosporozoite:*

236: sp-zoocyst:*

237: sp-bacteriophage:*

238: sp-organelle:*

239: sp-phage:*

240: sp-plant:*

241: sp-plantae:*

242: sp-virus:*

243: sp-zoobiont:*

244: sp-zooplankton:*

245: sp-zoophyte:*

246: sp-zoosporozoite:*

247: sp-zoocyst:*

248: sp-bacteriophage:*

249: sp-organelle:*

250: sp-phage:*

251: sp-plant:*

252: sp-plantae:*

253: sp-virus:*

254: sp-zoobiont:*

255: sp-zooplankton:*

256: sp-zoophyte:*

257: sp-zo

RESULT #	2	Application US/09480203
/ Sequence 3:	Application 3	
/ Patent No.	7,339,339	
/ INVENTOR INFORMATION:	T. W. Cohen	
/ APPLICANT INFORMATION:	T. W. Cohen	
/ ATTORNEY/AGENT INFORMATION:	Philip Cohen	
/ TITLE OF INVENTION: A PROTEIN PHOSPHATASE 1 BINDING PROTEIN		
/ FILING DATE:	2003-01-10	
/ CURRENT PUBLISHING NUMBER:	US2005/01480,203	
/ BARDINGER APPLICATION NUMBER:	09/300,327	
/ BARDINGER FILING DATE:	1999-04-07	
/ BARDINGER PATENT NUMBER:	6,717,906	
/ NUMBER OF SEQ ID NOS:	6	
/ SOFTWARE: PSSLSQ for Windows Version 3.0		
/ SEQ ID NO:		
/ TYPE: PPT		
/ ORGANISM: HOMO SAPIEENS		
US-09-480-203-3		
Query Match Similarity 100.0% Score 99. DB 3 / 37 Length 284;		
Best Local Similarity 100.0% Score 99. DB 3 / 37 Length 284;		
Matches 161 / Conservative 0 / Mismatches 0 / Indels 0;		
QY 1 PERPSTGTYKELPQY 16		
DB 269 FPPVGLLTLTLLTLLT 264		
RESULT #	3	Application US/09480203
/ Sequence 3	345..46	
/ Patent No.	6,658,945	
/ INVENTOR INFORMATION:	T. W. Cohen	
/ APPLICANT INFORMATION:	T. W. Cohen	
/ ATTORNEY/AGENT INFORMATION:	Philip Cohen	
/ FILE REFERENCE: US2005/01480,203		
/ CURRENT PUBLISHING NUMBER:	US2005/01480,203	
/ BARDINGER APPLICATION NUMBER:	09/300,327	
/ BARDINGER FILING DATE:	1999-05-19	
/ BARDINGER PATENT NUMBER:	6,717,906	
/ NUMBER OF SEQ ID NOS:	49	
/ SEQ ID NO:	46	
/ LENGTH:	700	
/ TYPE: PPT		
/ ORGANISM: MOUSE		
/ US-09-516-345-46		
Query Match Similarity 56.6% Score 56. DB 4 / 14 Length 700;		
Best Local Similarity 66.7% Score 56. DB 4 / 14 Length 700;		
Matches 21 / Conservative 2 / Mismatches 3 / Indels 0;		
QY 1 PERPSTGTYKELPQY 15		
DB 52 FPPVGLLTLTLLTLLT 56		
RESULT #	4	Application US/0876525
/ Sequence 7:	Application 7	
/ Patent No.	7,378,981	
/ INVENTOR INFORMATION:	GERALD L. JAMES	
/ APPLICANT INFORMATION:	Graham James	
/ ATTORNEY/AGENT INFORMATION:	Graham James	
/ TITLE OF INVENTION: NOVEL INTERLEUKIN-1 RECEPTOR AND INHIBITOR		
/ TITLE OF INVENTION: INTRACELLULAR LIGAND PROTEINS AND INHIBITORS		

PRIVACY:
 OTHER INFORMATION: Completely synthetic sequence
 US-09-939-847-12

Query Match 48.5%; Score 48; DB 4; Length 19;
 Best Local Similarity 61.5%; Pred: No. 0.5%;
 Matches 8; Conservative 1; Mismatches 4;
 Indels 0; Gaps 0;

QY 4 PSTRYDAGSYT 16
 111 1: 111 1
 Db 3 PSTRYDAGSYT 15

RESULT# 13
 Sequence 13, Application US/08933165A
 Patent No. 61239423

QY 4 PSTRYDAGSYT 16
 111 1: 111 1
 Db 3 PSTRYDAGSYT 15

RESULT# 13
 Sequence 13, Application US/08933165A
 Patent No. 61239423

QY 4 PSTRYDAGSYT 16
 111 1: 111 1
 Db 3 PSTRYDAGSYT 15

PRIVACY:
 OTHER INFORMATION: Completely synthetic sequence
 US-09-933-165-13

Query Match 48.5%; Score 48; DB 3; Length 21;
 Best Local Similarity 61.5%; Pred: No. 0.5%;
 Matches 8; Conservative 1; Mismatches 4;
 Indels 0; Gaps 0;

QY 4 PSTRYDAGSYT 16
 111 1: 111 1
 Db 5 PSTRYDAGSYT 17

RESULT# 14
 Sequence 13, Application US/09540448
 Patent No. 6403056

QY 4 PSTRYDAGSYT 16
 111 1: 111 1
 Db 5 PSTRYDAGSYT 17

PRIVACY:
 OTHER INFORMATION: Completely synthetic sequence
 US-09-540-448-13

Query Match 48.5%; Score 48; DB 4; Length 21;
 Best Local Similarity 61.5%; Pred: No. 0.5%;
 Matches 8; Conservative 1; Mismatches 4;
 Indels 0; Gaps 0;

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS

FILE REFERENCE: 2A831-301C

CURRENT APPLICATION NUMBER: US/09/840,707A

PRIORITY FILING DATE: 2001-04-23; 979

PRIORITY NUMBER: 09/162,977

PRIORITY NUMBER: 65/195,210

NUMBER OF SEQ ID NOS.: 26

SEQUENCE NUMBER: SEQ ID NO: 9

Publication No. US20030124625A1

GENERAL INFORMATION:

TITLE OF INVENTION: Novel Interleukin-1 Receptor

Intracellular Ligand Proteins and Inhibitors of Ligand

Number of Sequence: 7

Correspondence Address:

Address: IBM AFFILIATES GENETICS INSTITUTE, INC.

State: Cambridge Park Drive

City: Cambridge

Country: USA

State/Prov: MA

Postcode: 02149

Computer: IBM PC compatible

Medium Type: Floppy disk

Operating System: PC DOS/Windows

Copyright Holder: IBM Corp. Version #: 1.25

Application Number: US/09/984,519

Filing Date: 18-Jun-2001

Classification: <Unknown>

Prior Application Data:

Application Number: US/09/058,516

Registration Number: 32724

Attorney/Agent Name: Brown, Scott A.

Filing Date: <Unknown>

Priority/Parent Application:

Telephone: (617) 498-8224

Telex/Fax: (617) 498-8224

Information for SEQ ID No: 7:

Information for SEQ ID No: 7:

Source/Characteristics:

Length: 700 amino acids

Structure: Linear

Stereochemistry: D

Topology: Linear

Molecular Type: Protein

Hypothetical: No

Sequence Description: SEQ ID NO: 7;

US-09-848-313-7

Query Match: 51.5%

Score: 51

DB: 11

Best Local Similarity: 60.0%

Length: 709

Batches: 9

Indels: 0

Gaps: 0

Op: 1

PBMPIIGKLY 15

Db: 52 PATSAGKREFGPY 66

RESULT 8

US-10-038-557A-9

Sequence 9: Application US/1038557A

Publication Number: US20030126841

Applicant/CreatedBy: Terry M.

Title of Invention: Compositions and Methods for Treating Hemorrhagic Virus

Type: Peptide

File Reference: 24881-301D

Current Application Number: 09/162,055

Prior Application Number: 09/840,707

Prior Filing Date: 2000-01-23

Prior Application Number: 09/502,979

Prior Filing Date: 2000-04-27

Prior Application Number: 09/198,210

Prior Filing Date: 2000-04-27

Prior Application Number: 09/844,319

ENSG02201_2
ENSG02201 standard; Protein; 285 AA.
AM0220201;
25-SEPT-2004 (First entry)
phosphatase 1 protein-like protein; MEM65.
Phosphatase 1; MEM65; therapeutic; diagnostic; MEM2; Human; Alzheimer's disease; Parkinson's disease; cancer; nephrology; brain disorder; schizophrenia; stroke; diabetology; endocrinology; heart; lung disorder; brain disorder; schizophrenia; stroke; diabetes; endocrinology; heart; lung disorder; brain disorder; schizophrenia; stroke; vision-related disorder; nephrology; MEM7; MEM8; MEM9; MEM10; NERB8.

KW Alzheimer's disease; multiple sclerosis; benign prostate hyperplasia;
benign prostatic hyperplasia; gene therapy; cytotoxic;
urothelial carcinoma.

XX

DR WPI; 2002/1544/16.

DR N-SB#; ABX9770.

PP New calpain protein 12 with cysteine protease activity, useful for treating specific deficiency disorders -

XX

DR WPI; 2002/5374/57.

XX

PP New human calpain polypeptide, useful for treating peripheral and central nervous system disorder and benign prostate hyperplasia -

XX

DR WPI; 2002/5374/57.

XX

PP New calpain protein 12 standard; protein: 447 AA.

XX

DR WPI; 2002/103192-A1.

XX

PP New calpain protein 12 with cysteine protease activity, useful for treating specific deficiency disorders -

XX

CC Production of cap12; This sequence represents the calpain protease
CC splice variant cap12c described in the disclosure of the invention.

CC Sequence 4/2: AA:

SG Score 50; DB 23; Length 452;

Score 50; DB 23; Length 452;

Best Local Similarity 60.3%; Pred. No. 27;

Matches 1; Mismatches 4; Indels 0; Gaps 0;

Batch 13: AAM9718 standard; Protein: 518 AA.

XX

CC Query Match: 50.5%; Score 50; DB 23; Length 452;

CC Best Local Similarity 60.3%; Pred. No. 27;

CC Matches 1; Mismatches 4; Indels 0; Gaps 0;

CC Batch 13: AAM9718 standard; Protein: 518 AA.

CC XX

CC RESULT 1.4

CC ID AAM49717

CC Standard: Protein: 720 AA.

CC XX

CC AAM9717P;

CC DE Marine calpain protease 12 variant cap12a.

CC XX

CC Calpain protease cap12; splice variant; murine; gene therapy;

CC screening; diagnosis; cap12a.

CC Mus sp.

CC XX

CC Key Location/Qualifiers

CC Pkt: 43; SGO: 50;

CC Ksc-difference 1/60; Encoded by GCGCTG*

CC XX

CC DE010332-AL-

CC PD 10-JAN-2002.

CC XX

CC PR 30-JUN-2000; 2000008-103132.

CC XX

CC PA (BAD1) - BASF AG.

CC PA

CC Not given;

CC XX

CC DR WP; 2002115441/16.

CC DR

CC AB081661; AAS9765.

CC XX

CC New calpain protein 12 with cysteine protease activity, useful for

CC treating specific deficiency disorders.

CC XX

CC DE010332-AL-

CC PD 10-JAN-2002.

CC XX

CC PR 30-JUN-2000; 2000008-103132.

CC XX

CC PA (BAD1) - BASF AG.

CC PA

CC Not given;

CC XX

CC DR WP; 2002115441/16.

CC DR

CC AB081661; AAS9765.

CC XX

CC New calpain protease 12 with cysteine protease activity, useful for

CC treating specific deficiency disorders.

CC XX

CC DE010332-AL-

CC PD 10-JAN-2002.

CC XX

CC PR 30-JUN-2000; 2000008-103132.

CC XX

CC PA (BAD1) - BASF AG.

CC PA

CC Not given;

CC XX

CC DR WP; 2002115441/16.

CC DR

CC AB081661; AAS9765.

CC XX

CC New calpain protein 12 with cysteine protease activity, useful for

CC treating specific deficiency disorders.

CC XX

CC DE010332-AL-

CC PD 10-JAN-2002.

CC XX

CC PR 30-JUN-2000; 2000008-103132.

CC RESULT 1.5

CC ID AB091749

CC Standard: Protein: 82 AA.

CC XX

CC ABP10799 standard; Protein: 82 AA.

CC XX

CC ABP10799;

CC XX

CC DR 24-JUN-2002 (first entry)

CC DR Human ORF protein sequence SEQ ID NO:2500

CC XX

CC Human ORF reading frame: ORF1; gene therapy; cancer; cirrhosis;

CC hemangioma;

CC hyperplastic disorder; osteoarthritis; benign tumor; hemorrhage;

CC degenerative disorder; neurodegenerative disorder;

CC cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;

CC

CC Sequence 518 AA:

CC SeqW Match: 50.5%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

CC Length 518;

CC Mismatches 1;

CC Conservation 1;

CC Indels 0;

CC Gaps 0;

CC 0;

CC Sequence 518 AA:

CC SeqW Match: 50.3%; Score 50; DB 23;

KW hypertension; hyperthyroidism; cholesterol ester storage disease;

KW autoimmune disease; immunodeficiency; infectious disease; disease;

KW myasthenia gravis; Graves' disease; rheumatoid arthritis; autoimmune thyroiditis;

XX OS Homo sapiens;

XX OS WO00132523-A2.

XX PT (CIBA-1) CORAGEN CORP.

XX XX PI Shukerts RA, Leach MD;

XX XX DE 025-2002-106108/14.

XX XX WO91-084555.

XX XX Novel human polypeptides and polynucleotides useful for diagnosing,

PT preventing and treating cardiovascular disease, neurodegenerative,

PT hyperproliferative disorders and autoimmune disorders -

XX Disclosure, SEQ ID 21860; 1037PP; English.

CC The present invention describes substantially purified human proteins

CC (referred to as open reading frame, ORF, where X is 1-1491 (see Table 1

CC in the specification)) and 162 to AAB0752 encode the human ORF

CC proteins Gα10 and Gα11. Also described are nucleic acids useful for

CC diagnosis and treatment of diseases associated with these genes

CC in humans, and in the manufacture of a medicament for treating a

CC syndrome associated with ORX-associated disorder. ORX polyamide

CC sequences can be used in gene therapy. ORX sequences in the

CC present invention are useful for the treatment of liver,

CC prostate, breast, ovarian, endometrial, cervical, uterine, and rectal

CC transplantation, cardiovascular diseases, diabetes mellitus, systemic

CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester

CC storage disease, various lipoprotein deficiencies and disorders, infectious

CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid

CC disease, and rheumatism, glaucoma, eye diseases, eye diseases

CC useful for the treatment of inflammatory bowel disease, eye diseases

CC useful for treating burns, incisions, ulcers, for treating osteoporosis,

CC bone degenerative disorders, or periodontal disease and for gut

CC protection or regeneration and treatment of lung or liver fibrosis,

CC repeat insertion or deletion in various tissues and conditions resulting from

CC myxomatosis, or the like.

CC N.B. The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at [ftp://wipo.int/pub/published_pcf_sequences](http://wipo.int/pub/published_pcf_sequences).

XX Sequence 62 AA:

CC Query Match Score 48.5; DB 23; Length 62;

CC Best Local Similarity 60.0%; Pred. No. 7.1;

CC Matches 9; Conservative 3; Mismatches 2; Indels 1; Gaps 1;

CC Qy 1 PRYPSYL-TKEKGP 14

CC 32 PRYPSYL-TKEKGP 45

Db